l'Institut du Thorax
Bertrand Cariou has not added Biography.
If you are Bertrand Cariou and would like to personalize this page please email our Author Liaison for assistance.
Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14.
The Journal of biological chemistry Feb, 2002 | Pubmed ID: 11726652
The adapter protein ZIP binds Grb14 and regulates its inhibitory action on insulin signaling by recruiting protein kinase Czeta.
Molecular and cellular biology Oct, 2002 | Pubmed ID: 12242277
Inhibition of FGF receptor signalling in Xenopus oocytes: differential effect of Grb7, Grb10 and Grb14.
FEBS letters Jul, 2003 | Pubmed ID: 12885405
Cellular and molecular mechanisms of adipose tissue plasticity in muscle insulin receptor knockout mice.
Endocrinology Apr, 2004 | Pubmed ID: 14684612
Regulation and functional roles of Grb14.
Frontiers in bioscience : a journal and virtual library May, 2004 | Pubmed ID: 14977573
Increased adipose tissue expression of Grb14 in several models of insulin resistance.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Jun, 2004 | Pubmed ID: 15059968
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties.
Circulation research Dec, 2004 | Pubmed ID: 15539630
Farnesoid X receptor: a new player in glucose metabolism?
Endocrinology Mar, 2005 | Pubmed ID: 15713939
Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.
Biochimie Jan, 2005 | Pubmed ID: 15733743
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition.
The Journal of biological chemistry Aug, 2005 | Pubmed ID: 15899888
Transient impairment of the adaptive response to fasting in FXR-deficient mice.
FEBS letters Aug, 2005 | Pubmed ID: 16023103
Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases.
Surgery Dec, 2005 | Pubmed ID: 16360406
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.
The Journal of biological chemistry Mar, 2006 | Pubmed ID: 16407292
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice.
The Journal of biological chemistry Apr, 2006 | Pubmed ID: 16446356
The expanding role of the bile acid receptor FXR in the small intestine.
Journal of hepatology Jun, 2006 | Pubmed ID: 16618512
FXR: More than a bile acid receptor?
Endocrinology Sep, 2006 | Pubmed ID: 16912235
FXR: a promising target for the metabolic syndrome?
Trends in pharmacological sciences May, 2007 | Pubmed ID: 17412431
FXR-deficiency confers increased susceptibility to torpor.
FEBS letters Nov, 2007 | Pubmed ID: 17950284
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
The Journal of biological chemistry Apr, 2008 | Pubmed ID: 18245819
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.
FEBS letters Mar, 2008 | Pubmed ID: 18298956
PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
Trends in biochemical sciences Sep, 2008 | Pubmed ID: 18672372
Role of bile acids and bile acid receptors in metabolic regulation.
Physiological reviews Jan, 2009 | Pubmed ID: 19126757
Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia.
Arteriosclerosis, thrombosis, and vascular biology May, 2009 | Pubmed ID: 19265033
A corticotroph pituitary adenoma as the initial presentation of familial glucocorticoid deficiency.
European journal of endocrinology Jul, 2009 | Pubmed ID: 19423561
High protein intake reduces intrahepatocellular lipid deposition in humans.
The American journal of clinical nutrition Oct, 2009 | Pubmed ID: 19710199
PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.
Arteriosclerosis, thrombosis, and vascular biology Dec, 2009 | Pubmed ID: 19762784
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
Biochemical and biophysical research communications Dec, 2009 | Pubmed ID: 19878649
[Cholesterol metabolism and beta-cell function].
Medecine sciences : M/S Apr, 2010 | Pubmed ID: 20412743
Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients.
Atherosclerosis Aug, 2010 | Pubmed ID: 20452593
The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways.
The Journal of biological chemistry Nov, 2010 | Pubmed ID: 20851881
[Dyslipidemia].
La Revue du praticien Jan, 2011 | Pubmed ID: 21452556
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity.
Diabetes Jul, 2011 | Pubmed ID: 21593203
Clinical aspects of PCSK9.
Atherosclerosis Jun, 2011 | Pubmed ID: 21596380
Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults.
Nutrition & metabolism Jul, 2011 | Pubmed ID: 21736725
Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.
Diabetes care Sep, 2011 | Pubmed ID: 21816979
Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
Atherosclerosis Nov, 2011 | Pubmed ID: 21889145
[Management of hypercholesterolemia: what target for LDL cholesterol?].
La Revue du praticien Oct, 2011 | Pubmed ID: 22135977
DPP-4 inhibitors in the treatment of type 2 diabetes.
Biochemical pharmacology Apr, 2012 | Pubmed ID: 22172989
Thiazolidinediones and PPARγ agonists: time for a reassessment.
Trends in endocrinology and metabolism: TEM May, 2012 | Pubmed ID: 22513163
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine Aug, 2012 | Pubmed ID: 22743249
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Diabetes care Dec, 2012 | Pubmed ID: 23043166
New avenues for the pharmacological management of type 2 diabetes: an update.
Annales d'endocrinologie Nov, 2012 | Pubmed ID: 23078974
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.
Nutrition & metabolism Jan, 2013 | Pubmed ID: 23298392
Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury.
The Journal of clinical endocrinology and metabolism Apr, 2013 | Pubmed ID: 23450051
Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes.
Molecular and cellular biology Jun, 2013 | Pubmed ID: 23530060
Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.
Arteriosclerosis, thrombosis, and vascular biology Jul, 2013 | Pubmed ID: 23559630
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.) Dec, 2013 | Pubmed ID: 23703580
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.
Diabetes care Oct, 2013 | Pubmed ID: 23715754
Function of seipin: new insights from Bscl2/seipin knockout mouse models.
Biochimie Jan, 2014 | Pubmed ID: 23831461
A standardized vascular disease health check in europe: a cost-effectiveness analysis.
PloS one , 2013 | Pubmed ID: 23869204
Surgery for 'asymptomatic' mild primary hyperparathyroidism improves some clinical symptoms postoperatively.
European journal of endocrinology Nov, 2013 | Pubmed ID: 23956299
Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism.
European journal of endocrinology Feb, 2014 | Pubmed ID: 24154684
Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.
The Journal of clinical endocrinology and metabolism Feb, 2014 | Pubmed ID: 24276449
[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
Bulletin du cancer Feb, 2014 | Pubmed ID: 24557872
Congenital lipodystrophies and dyslipidemias.
Current atherosclerosis reports Sep, 2014 | Pubmed ID: 25047893
Preserved adrenal function in fully PCSK9-deficient subject.
International journal of cardiology Sep, 2014 | Pubmed ID: 25062564
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
Expert opinion on investigational drugs Oct, 2014 | Pubmed ID: 25164277
The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.
Diabetes & vascular disease research Nov, 2014 | Pubmed ID: 25212694
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
BMC cardiovascular disorders Sep, 2014 | Pubmed ID: 25240705
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Lancet (London, England) Jan, 2015 | Pubmed ID: 25282519
Long-term effects of Roux-en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in female non diabetic subjects: A cross-sectional pilot study.
Clinical nutrition (Edinburgh, Scotland) Oct, 2015 | Pubmed ID: 25306425
[Trans-intestinal cholesterol excretion (TICE): a new route for cholesterol excretion].
Medecine sciences : M/S Oct, 2014 | Pubmed ID: 25311025
[Hormonal evaluation of adrenal incidentalomas].
Annales de biologie clinique Nov-Dec, 2014 | Pubmed ID: 25486661
PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension.
Atherosclerosis Mar, 2015 | Pubmed ID: 25621930
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
European heart journal May, 2015 | Pubmed ID: 25687353
Management of thyroid nodules incidentally discovered on MIBI scanning for primary hyperparathyroidism.
Langenbeck's archives of surgery Apr, 2015 | Pubmed ID: 25694271
Laparoscopic Gastric Banding in Obese Patients with Sleep Apnea: A 3-Year Controlled Study and Follow-up After 10 Years.
Obesity surgery Oct, 2015 | Pubmed ID: 25702144
Role of PCSK9 beyond liver involvement.
Current opinion in lipidology Jun, 2015 | Pubmed ID: 25887680
Letter from Le May and Cariou regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms".
Circulation May, 2015 | Pubmed ID: 25940972
Clinical use of insulin degludec.
Diabetes research and clinical practice Jul, 2015 | Pubmed ID: 25963320
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
Diabetologia Sep, 2015 | Pubmed ID: 26049403
Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels.
Clinical therapeutics Sep, 2015 | Pubmed ID: 26278513
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.
Circulation. Cardiovascular genetics Dec, 2015 | Pubmed ID: 26374825
mTOR inhibitors and diabetes.
Diabetes research and clinical practice Nov, 2015 | Pubmed ID: 26421362
Vitamin D deficiency is an independent risk factor for PTDM after kidney transplantation.
Transplant international : official journal of the European Society for Organ Transplantation Feb, 2016 | Pubmed ID: 26426441
Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes.
Diabetologia Jan, 2016 | Pubmed ID: 26486355
Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Expert opinion on investigational drugs , 2015 | Pubmed ID: 26548423
Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Disease models & mechanisms Jan, 2016 | Pubmed ID: 26586530
PCSK9 Inhibition: Does Lipoprotein Size Matter?
Journal of the American Heart Association Nov, 2015 | Pubmed ID: 26586733
[A YOUNG MAN WHOSE LDL-CHOLESTEROL IS GREATER THAN 1.9 G/L].
La Revue du praticien Oct, 2015 | Pubmed ID: 26749708
Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.
Atherosclerosis Jul, 2016 | Pubmed ID: 27179706
Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.
Journal of diabetes and its complications Sep-Oct, 2016 | Pubmed ID: 27267268
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
Diabetes care Sep, 2016 | Pubmed ID: 27311491
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.
European heart journal Oct, 2016 | Pubmed ID: 27460890
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
Diabetes, obesity & metabolism Nov, 2016 | Pubmed ID: 27486125
FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency.
Diabetes Nov, 2016 | Pubmed ID: 27554469
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials.
International journal of cardiology Nov, 2016 | Pubmed ID: 27573600
PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering.
Atherosclerosis Oct, 2016 | Pubmed ID: 27591126
Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.
Diabetes, obesity & metabolism Mar, 2017 | Pubmed ID: 27804190
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
The lancet. Diabetes & endocrinology Feb, 2017 | Pubmed ID: 27908689
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Diabetes & metabolism Oct, 2019 | Pubmed ID: 30615985
Severely uncontrolled diabetes: a new aetiology of acquired bisalbuminaemia.
Diabetes & metabolism Sep, 2020 | Pubmed ID: 30660760
EGF-A peptides: A promising strategy for PCSK9 inhibition.
Atherosclerosis Jan, 2020 | Pubmed ID: 31784031
Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes.
Metabolism: clinical and experimental Feb, 2020 | Pubmed ID: 31785259
Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes.
Atherosclerosis Jan, 2020 | Pubmed ID: 31835041
Association between sleep disturbances, fear of hypoglycemia and psychological well-being in adults with type 1 diabetes mellitus, data from cross-sectional VARDIA study.
Diabetes research and clinical practice Feb, 2020 | Pubmed ID: 31866527
Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes.
The Journal of clinical endocrinology and metabolism Jul, 2020 | Pubmed ID: 32301490
Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.
Diabetologia Aug, 2020 | Pubmed ID: 32472191
Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.
Diabetologia Sep, 2020 | Pubmed ID: 32617649
Euglycaemic ketoacidosis during gestational diabetes with concomitant COVID-19 infection.
Diabetes & metabolism Mar, 2021 | Pubmed ID: 32738403
Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 2020;43:1399-1407.
Diabetes care Oct, 2020 | Pubmed ID: 32958626
Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study.
Diabetes & metabolism Mar, 2021 | Pubmed ID: 33091555
Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study.
Diabetes research and clinical practice May, 2021 | Pubmed ID: 33577905
Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study.
Diabetologia Apr, 2021 | Pubmed ID: 33599800
Impact of parathyroidectomy on cardiovascular risk in primary hyperparathyroidism: A narrative review.
Nutrition, metabolism, and cardiovascular diseases : NMCD Apr, 2021 | Pubmed ID: 33612382
PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs.
Stem cell reports Dec, 2021 | Pubmed ID: 34739847
Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes.
Cardiovascular diabetology Feb, 2022 | Pubmed ID: 35130909
Transintestinal cholesterol excretion in health and disease.
Current atherosclerosis reports Mar, 2022 | Pubmed ID: 35138569
COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study.
Current diabetes reports Feb, 2022 | Pubmed ID: 35171448
Generation of a GPR146 knockout human induced pluripotent stem cell line (ITXi001-A-1).
Stem cell research Apr, 2022 | Pubmed ID: 35247835
CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants.
International journal of molecular sciences Apr, 2022 | Pubmed ID: 35457099
Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort.
Cardiovascular diabetology Jun, 2022 | Pubmed ID: 35681209
Impact of diabetes on COVID-19 prognosis beyond comorbidity burden: the CORONADO initiative.
Diabetologia Sep, 2022 | Pubmed ID: 35701673
Identification of a Gain-of-Function Variant as a Novel Cause of Familial Combined Hypocholesterolemia.
Circulation Sep, 2022 | Pubmed ID: 35899625
PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: Role of hepatic cholesterol.
Biochimica et biophysica acta. Molecular and cell biology of lipids Dec, 2022 | Pubmed ID: 35985474
Effect of the LDL receptor mutation type on incident major adverse cardiovascular events in familial hypercholesterolaemia.
European journal of preventive cardiology Nov, 2022 | Pubmed ID: 36047048
Variants in the Gene Are Associated With a Favorable Cardiometabolic Risk Profile.
Arteriosclerosis, thrombosis, and vascular biology Oct, 2022 | Pubmed ID: 36047410
Associations of microvascular complications with all-cause death in patients with diabetes and COVID-19: The CORONADO, ABCD COVID-19 UK national audit and AMERICADO study groups.
Diabetes, obesity & metabolism Jan, 2023 | Pubmed ID: 36053971
FACS-assisted CRISPR-Cas9 genome editing of human induced pluripotent stem cells.
STAR protocols Dec, 2022 | Pubmed ID: 36115027
Effects of parathyroidectomy on kidney function in patients with primary hyperparathyroidism: Results of a prospective study.
Surgery Jan, 2023 | Pubmed ID: 36167701
Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study.
Diabetes & metabolism Jan, 2023 | Pubmed ID: 36174852
Renal function decline and heart failure hospitalisation in patients with type 2 diabetes: Dynamic predictions from the prospective SURDIAGENE cohort.
Diabetes research and clinical practice Dec, 2022 | Pubmed ID: 36375567
A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia.
Translational research : the journal of laboratory and clinical medicine Dec, 2022 | Pubmed ID: 36528340
Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE study.
Archives of cardiovascular diseases Jan, 2023 | Pubmed ID: 36535853
Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort.
Metabolism: clinical and experimental Jan, 2023 | Pubmed ID: 36731720
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유